| Tracie A Abplanalp, CRNA | |
|
300 3rd Ave Se, Magee, MS 39111-3665 | |
| (601) 849-7303 | |
| Not Available |
| Full Name | Tracie A Abplanalp |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 13 Years |
| Location | 300 3rd Ave Se, Magee, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972875110 | NPI | - | NPPES |
| RN204602 | Other | GA | GA LICENSE NUMBER |
| R892422 | Other | MS | APRN LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN204602 (Georgia) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | R892422 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastrointestinal Associates Pa | 5294795241 | 90 |
News Archive
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
LogisticsWeek looks at how "PEPFAR's Supply Chain Management System, a project made up of 13 health and development institutions working to procure and provide quality essential medicines at affordable prices," has been able to assist countries in quickly scaling up HIV/AIDS treatment.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
› Verified 1 days ago
| Entity Name | Magee Benevolent Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225157258 PECOS PAC ID: 3678466463 Enrollment ID: O20040205000400 |
News Archive
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
LogisticsWeek looks at how "PEPFAR's Supply Chain Management System, a project made up of 13 health and development institutions working to procure and provide quality essential medicines at affordable prices," has been able to assist countries in quickly scaling up HIV/AIDS treatment.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
› Verified 1 days ago
| Entity Name | Hattiesburg Gi Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730293234 PECOS PAC ID: 8921083288 Enrollment ID: O20040622000367 |
News Archive
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
LogisticsWeek looks at how "PEPFAR's Supply Chain Management System, a project made up of 13 health and development institutions working to procure and provide quality essential medicines at affordable prices," has been able to assist countries in quickly scaling up HIV/AIDS treatment.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
› Verified 1 days ago
| Entity Name | Gastrointestinal Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093765604 PECOS PAC ID: 5294795241 Enrollment ID: O20041013001263 |
News Archive
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
LogisticsWeek looks at how "PEPFAR's Supply Chain Management System, a project made up of 13 health and development institutions working to procure and provide quality essential medicines at affordable prices," has been able to assist countries in quickly scaling up HIV/AIDS treatment.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
› Verified 1 days ago
| Entity Name | Southern Anesthesia Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780025767 PECOS PAC ID: 7214163724 Enrollment ID: O20131111001145 |
News Archive
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
LogisticsWeek looks at how "PEPFAR's Supply Chain Management System, a project made up of 13 health and development institutions working to procure and provide quality essential medicines at affordable prices," has been able to assist countries in quickly scaling up HIV/AIDS treatment.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tracie A Abplanalp, CRNA 97 Terrell Rd, Prentiss, MS 39474-3066 Ph: (601) 596-4768 | Tracie A Abplanalp, CRNA 300 3rd Ave Se, Magee, MS 39111-3665 Ph: (601) 849-7303 |
News Archive
MR arthrography of the shoulder allows physicians to better identify tears and provides patients with an accurate diagnosis to determine whether or not surgery is needed, according to a study performed at Neuroskeletal Imaging in Merritt Island, Florida.
Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
LogisticsWeek looks at how "PEPFAR's Supply Chain Management System, a project made up of 13 health and development institutions working to procure and provide quality essential medicines at affordable prices," has been able to assist countries in quickly scaling up HIV/AIDS treatment.
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
› Verified 1 days ago
Mr. David J Ware Ii, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 2nd Street Se, Magee, MS 39111 Phone: 601-849-5070 | |
Audrey Donna Ghatas, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 300 3rd Ave Se, Magee, MS 39111 Phone: 601-849-7173 Fax: 601-849-7353 |